GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nipro Corp (FRA:5FA) » Definitions » Cyclically Adjusted PS Ratio

Nipro (FRA:5FA) Cyclically Adjusted PS Ratio : 0.44 (As of Jun. 10, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nipro Cyclically Adjusted PS Ratio?

As of today (2024-06-10), Nipro's current share price is €7.15. Nipro's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was €16.25. Nipro's Cyclically Adjusted PS Ratio for today is 0.44.

The historical rank and industry rank for Nipro's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:5FA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.41   Med: 0.61   Max: 0.99
Current: 0.48

During the past years, Nipro's highest Cyclically Adjusted PS Ratio was 0.99. The lowest was 0.41. And the median was 0.61.

FRA:5FA's Cyclically Adjusted PS Ratio is ranked better than
86.37% of 477 companies
in the Medical Devices & Instruments industry
Industry Median: 2.17 vs FRA:5FA: 0.48

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Nipro's adjusted revenue per share data for the three months ended in Dec. 2023 was €5.304. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €16.25 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Nipro Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Nipro's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nipro Cyclically Adjusted PS Ratio Chart

Nipro Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.65 0.65 0.46 0.42 -

Nipro Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.41 0.48 0.43 -

Competitive Comparison of Nipro's Cyclically Adjusted PS Ratio

For the Medical Instruments & Supplies subindustry, Nipro's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nipro's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nipro's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nipro's Cyclically Adjusted PS Ratio falls into.



Nipro Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Nipro's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=7.15/16.25
=0.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nipro's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Nipro's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=5.304/106.8000*106.8000
=5.304

Current CPI (Dec. 2023) = 106.8000.

Nipro Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 3.264 95.700 3.643
201406 3.215 98.000 3.504
201409 3.378 98.500 3.663
201412 3.437 97.900 3.749
201503 3.847 97.900 4.197
201506 3.742 98.400 4.061
201509 3.997 98.500 4.334
201512 4.205 98.100 4.578
201603 4.336 97.900 4.730
201606 4.030 98.100 4.387
201609 4.163 98.000 4.537
201612 4.115 98.400 4.466
201703 4.045 98.100 4.404
201706 4.097 98.500 4.442
201709 3.897 98.800 4.213
201712 4.325 99.400 4.647
201803 4.231 99.200 4.555
201806 4.373 99.200 4.708
201809 4.398 99.900 4.702
201812 4.897 99.700 5.246
201903 4.643 99.700 4.974
201906 4.990 99.800 5.340
201909 5.290 100.100 5.644
201912 5.220 100.500 5.547
202003 5.452 100.300 5.805
202006 4.990 99.900 5.335
202009 5.059 99.900 5.408
202012 5.221 99.300 5.615
202103 5.424 99.900 5.799
202106 5.454 99.500 5.854
202109 5.872 100.100 6.265
202112 5.372 100.100 5.732
202203 5.223 101.100 5.517
202206 4.907 101.800 5.148
202209 5.073 103.100 5.255
202212 5.546 104.100 5.690
202303 5.275 104.400 5.396
202306 4.988 105.200 5.064
202309 5.001 106.200 5.029
202312 5.304 106.800 5.304

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nipro  (FRA:5FA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Nipro Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Nipro's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nipro (FRA:5FA) Business Description

Traded in Other Exchanges
Address
3-9-3 Honjo-Nishi Kita-ku, Osaka, JPN, 531-8510
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.

Nipro (FRA:5FA) Headlines

No Headlines